Clinical applications of commonly used contemporary antidotes. A US perspective

Drug Safety

Volumn 16, Issue 1, 1997, Pages 9-47

  Bowden, Carol A ^a   Krenzelok, Edward P ^b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACTIVATED CARBON; ALCOHOL; ANTIDOTE; ATROPINE; CALCIUM SALT; DEFEROXAMINE; DIGOXIN ANTIBODY F(AB) FRAGMENT; DIMERCAPROL; EDETIC ACID; FLUMAZENIL; FOLIC ACID; GLUCAGON; HYDROXOCOBALAMIN; METHYLENE BLUE; NALOXONE; NEOSTIGMINE; OPIATE; PARACETAMOL; PENICILLAMINE; PHYSOSTIGMINE SALICYLATE; PHYTOMENADIONE; PRALIDOXIME CHLORIDE; PYRIDOXINE; SODIUM NITRITE; SODIUM THIOSULFATE; SUCCIMER; THIOCTIC ACID; UNINDEXED DRUG; VENOM ANTISERUM;

ADVERSE DRUG REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BRADYCARDIA; BRONCHOSPASM; CARDIOTOXICITY; COST BENEFIT ANALYSIS; CYANIDE POISONING; DIAPHORESIS; DIARRHEA; DISORIENTATION; DRUG COST; DRUG FORMULATION; DRUG INTOXICATION; DRUG MECHANISM; GASTRITIS; HUMAN; HYPERTHERMIA; HYPOTENSION; INTOXICATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEIZURE; SNAKEBITE; STOMACH LAVAGE; SUBCUTANEOUS DRUG ADMINISTRATION; TACHYCARDIA; UNITED STATES; VERTIGO; VOMITING;

EID: 0031026846     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199716010-00002     Document Type: Review

References (186)

1. Litovitz TL, Felberg L, White S, et al. 1995 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1996; 14: 487-537
2. Litovitz TL, Felberg L, Soloway RA, et al. 1994 annual report of the American Association of Poison Control Centers Toxic-Exposure Surveillance System. Am J Emerg Med 1995; 13: 551-97
3. Litovitz T, Veltri JC. 1984 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1985; 3: 423-50
4. Litovitz TL, Normann SA, Veltri JC. 1985 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1986; 4: 427-58
5. Litovitz TL, Martin TG, Schmitz B. 1986 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1987; 5: 405-45
6. Litovitz TL, Schmitz BF, Matyunas N, et al. 1987 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1988; 6: 479-515
7. Litovitz TL, Schmitz BF, Holm KC. 1988 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1989; 7: 495-545
8. Litovitz TL, Schmitz BF, Bailey KM. 1989 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1990; 8: 394-442
9. Litovitz TL, Bailey KM, Schmitz BF, et al. 1990 annual report of the American Association of Poison Control Centers National Data Collection system. Am J Emerg Med 1991; 9: 461-509
10. Litovitz TL, Holm KC, Bailey KM, et al. 1991 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1992; 10: 452-505
11. Litovitz TL, Holm KC, Clancy C, et al. 1992 annual report of the American Association of Poison Control Centers Toxic-Exposure Surveillance System. Am J Emerg Med 1993; 11: 494-555
12. Litovitz TL, Clark LR, Soloway RA. 1993 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1994; 12: 546-84
13. Veltri JC, Litovitz TL. 1983 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1984; 2: 420-43
14. Krenzelok EP, Leikin JB. Approach to the poisoned patient. Dis Month 1996; 42: 511-607
15. Hoffman JR, Schringer DL, Luo JS. The empiric use of naloxone in patients with altered mental status: a reappraisal. Ann Emerg Med 1991; 20: 246-52
16. Redbook®. Montvale, NJ: Medical Economics. 1995
17. Smilkstein MJ, Knapp GL, Kulig KW, et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose: analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988; 319: 1557-62
18. Lewis RK, Paloucek FP. Assessment and treatment of acetaminophen overdose. Clin Pharm 1991; 10: 765-74
19. Prescott LF, Roscoe P, Wright N, et al. Plasma paracetamol half-life and hepatic necrosis in patients with paracetamol overdosage. Lancet 1971; I: 519-22
20. Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet 1995; 346: 547-52
21. Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics 1975; 55: 871-6
22. Dey Laboratories, Inc. Mucosil product information. Napa, CA: Dey Laboratories, Inc., March 1991
23. Chamberlain JM, Gorman RL, Oderda GM, et al. Use of activated charcoal in a simulated poisoning with acetaminophen: a new loading dose for N-acetylcysteine? Ann Emerg Med 1993; 22: 1398-402
24. Smilkstein MJ. A new loading dose for N-acetylcysteine? The answer is no (correspondence). Arm Emerg Med 1994; 24: 538-9
25. Brent J. Are activated charcoal-N-acetylcysteine interactions of clinical significance? Ann Emerg Med 1993; 22: 1860-1
26. North DS, Peterson RG, Krenzelok EP. Effect of activated charcoal administration on acetylcysteine scrum levels in humans. Am J Hosp Pharm 1981; 38: 1022-4
27. Rybolt TR, Burrell DE, Shults JM, et al. In vitro coadsorption of acetaminophen and N-acetylcysteine onto activated carbon powder. J Pharm Sci 1986; 75: 904-6
28. Rose SR. Subtleties of managing acetaminophen poisoning. Am J Hosp Pharm 1994; 51: 3065-8
29. Flanagan RJ, Meredith TJ. Use of N-acetylcysteine in clinical toxicology. Am J Med 1991; 91 Suppl. 3C: 131S-9S
30. Smilkstein MJ, Bronstein AC, Linden C, et al. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med 1991; 20: 1058-63
31. Harrison PM, Keays R, Bray GP, et al. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990; 335: 1572-3
32. Keays R, Harrison PM, Wendon JA, et al. Intravenous acetylcysteine in paracetamol-induced fulminant hepatic failure: a prospective controlled trial. Br Med J 1991; 303: 1026-9
33. Jaimovich DG. Transport management of the patient with acute poisoning. Pediatr Clin North Am 1993; 40: 407-30
34. Alam SN, Roberts RJ, Fisher LJ. Age related differences in salicylamide and acetaminophen conjugation in man. J Pediatr 1977; 90: 130
35. Peterson RG, Rumack BH. Age as a variable in acetaminophen overdose. Arch Intern Med 1981; 141: 390-3
36. Peterson RG, Rumack BH. Pharmacokinetics of acetaminophen in children. Pediatrics 1978; 62: 877-9
37. Fine JS, Goldfrank LR. Update in medical toxicology. Pediatr Clin North Am 1992; 39: 1031-51
38. Fiser DH, Moss MM, Walker W. Critical care for clonidine poisoning in toddlers. Crit Care Med 1990; 18: 1124-8
39. Chamberlain JM, Klein BL. A comprehensive review of naloxone for the emergency physician. Am J Emerg Med 1994; 12: 650-60
40. Bernstein JE, Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 1979; 115: 1366-7
41. Martin WR. Naloxone. Ann Intern Med 1976; 85: 765-8
42. Wahlstrom A, Winblad B, Bixo M, et al. Human brain metabolism of morphine and naloxone. Pain 1988; 35: 121-7
43. Litovitz TL. The anecdotal antidotes. Emerg Med Clin North Am 1984; 2: 145-58
44. Lewis JM, Klein-Schwarlz W, Benson BE. Continuous naloxone infusion in pediatric narcotic overdose. Am J Dis Child 1984; 138: 944-6
45. Romac DR. Safety of prolonged, high-dose infusion of naloxone hydrochloride for severe methadone overdose. Clin Pharm 1986; 5: 251-4
46. Goldfrank L. Weisman RS, Errick JK, et al. Ann Emerg Med 1986; 15: 566-70
47. Bradberry JC, Raebel MA. Continuous infusion of naloxone in the treatment of narcotic overdose. Drug Intell Clin Pharm 1981; 15: 945-50
48. Osterwalder JJ. Naloxone - for intoxications with intravenous heroin and heroin mixtures - harmless or hazardous? A prospective clinical study. Clin Toxicol 1996; 34: 409-16
49. Cuss FM, Colaeo CB, Baron JH. Cardiac arrest after reversal of effects of opiates with naloxone. Br Med J 1984; 288: 363-4
50. Neal JM, Owens BD, Wright SW. Hazards of antagonizing narcotic sedation with naloxone [letter]. Ann Emerg Med 1993; 22: 145-6
51. Gremse DA, Artman M, Boerth RC. Hypertension associated with naloxone treatment for clonidine poisoning. J Pediatr 1986; 108: 776-8
52. Powers RD, Donowitz LG. Endotracheal administration of emergency medications. South Med J 1984; 77: 340-1
53. Tandberg D, Abercrombie D. Treatment of heroin overdose with endotracheal naloxone. Ann Emerg Med 1982; 11; 443-5
54. Doyon S, Roberts JR. Reappraisal of the 'coma cocktail': dextrose, flumazenil, naloxone and thiamine. Emerg Med Clin North Am 1994; 12: 301-16
55. Kuplan JL, Marx JA. Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study. Ann Emerg Med 1993; 22: 187-90
56. DeBleecker J, Van Den Neucker K, Willems J. The intermediate syndrome in organophosphate poisoning: presentation of a case and review of the literature. J Toxicol Clin Toxicol 1992; 30: 321-9; 331-2
57. DeBleecker J, Van Den Neucker K, Colardyn F. Intermediate syndrome in organophosphorus poisoning: a prospective study. Crit Care Med 1993; 21: 1706-11
58. Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus insecticides: an intermediate syndrome. N Engl J Med 1987; 316: 761-3
59. Haddad LM. Organophosphate poisoning - intermediate syndrome [editorial]. Clin Toxicol 1992; 30: 331-2
60. Marrs TC. Organophosphate poisoning. Pharmacol Ther 1993; 58: 51-66
61. Ellenhorn MJ, Barceloux DG. Medical toxicology: diagnosis and treatment of human poisoning. New York: Elsevier, 1988
62. Fuortes LJ, Ayeho AD, Kross BC. Cholinesterase-inhibiting insecticide toxicity. Am Fam Physician 1993; 15; 47: 1613-20
63. Ali-Melkkila T, Kanto J, Lisalo E. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand 1993; 37: 633-42
64. Lotti M. Treatment of acute organophosphate poisoning. Med J Aust 1991; 154: 51-5
65. Orma PS, Middleton RK. Aerosolized atropine as an antidote to nerve gas. Ann Pharmacother 1992; 26: 937-8
66. Rumack BH, Spoerke DG, editors. POISINDEX Information System. Denver, Colorado: MICROMEDEX, Inc., edition expires 31 August 1996
67. Bardin PG, van Eeden SF, Moolman JA, et al. Organophosphate and carbamate poisoning. Arch Intern Med 1994; 154: 1433-41
68. Shockley LW. The use of inhaled nebulized atropine for the treatment of malathion poisoning. Clin Toxicol 1989; 27: 183-92
69. Mills KC, Curry SC. Acute iron poisoning. Emerg Med Clin North Am 1994; 12: 397-413
70. Swartz RD. Deferoxamine and aluminum removal. Am J Kidney Dis 1985; 6: 358-64
71. Alfrey AC. Dialysis encephalopathy. Kidney Int 1986; 29 Suppl. 18: 53-7
72. Curry SC. Iron. In: Reisdorff EJ, Roberts MR, Wiegenstein JG, editors. Pediatric Emergency Medicine. Philadelphia: WB Saunders, 1993: 673-9
73. Fargion S, Taddei MT, Abutti V, et al. Early iron overload in beta-thalassaemia major: when to start chelation therapy? Arch Dis Child 1982; 57: 929-33
74. Pippard MJ. Desferrioxamine-induced iron excretion in humans. Bailliere's Clin Haematol 1989; 2: 323-42
75. FaIk RJ, Mattern WD, Lamanna RG, et al. Iron removal during C.A.P.D. using deferoxamine. Kidney Int 1983; 24: 110-2
76. Oliveri NF, Buncic R, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986; 314: 869-73
77. Cheney K, Gumbiner C, Benson B, et al. Survival after a severe iron poisoning treated with intermittent infusions of deferoxamine. J Toxicol Clin Toxicol 1995; 33: 61-6
78. Tenenbein M, Kowalski S, Sienko A, et al. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet 1992; 339: 699-701
79. Adamson IY, Sienko A, Tenenbein M. Pulmonary toxicity of deferoxamine in iron-poisoned mice. Toxicol Appl Pharmacol 1993; 120: 13-9
80. Kirking MH. Treatment of chronic iron overload. Clin Pharm 1991; 10: 775-83
81. Turk J, Aks S, Ampuero F, et al. Successful therapy of iron intoxication in pregnancy with intravenous deferoxamine and whole bowel irrigation. Vet Hum Toxicol 1993; 35: 441-4
82. Vaskaridou E, Konstantopoulos K, Kyriakou D, et al. Deferoxamine treatment during early pregnancy: absence of teratogenicity in two cases. Haematologica 1993; 78: 183-4
83. Blake DR, Winyard P, Lunec J, et al. Cerebral and ocular toxicity induced by desferrioxamine. Q J Med 1985; 219: 345-55
84. Banner W, Tong TG. Iron poisoning. Pediatr Clin North Am 1986; 33: 393-409
85. Johnson CA. Management of snakebite. Am Fam Physician 1991; 44: 174-80
86. Russel FE. Injuries by venomous animals [abstract]. Ann Intern Med 1964; 61: 803
87. Gold BS, Barish RA. Venomous snakebites: current concepts in diagnosis, treatment and management. Emerg Med Clin North Am 1992; 10: 249-67
88. Gold BS, Wingert WA. Snake venom poisoning in the US: a review of therapeutic practice. South Med J 1994; 87: 579-89
89. Wyeth Laboratories, Inc. Antivenin (Crotalidae) Polyvalent (equine origin) product information. Marietta, PA: Wyeth Laboratories, Inc., 1986
90. Blackman JR, Dillon S. Venomous snakebite: past, present and future treatment options. J Am Board Fam Pract 1992; 5: 399-405
91. Davidson TM, Schafer SF. Rattlesnake bites: guidelines for aggressive treatment. Postgrad Med 1994; 96: 107-14
92. Schauben JL, Frenia ML. Update on antidotal therapy. J Pharm Pract 1993; 2: 63-73
93. Parrish HM, Kahn MS. Snakebite during pregnancy. Obstet Gynecol 1966; 27: 468-71
94. Egen N, Russell F, Consroe P, et al. A new ovine Fab antivenom for north american venomous snakes [abstract]. Vet Hum Toxicol 1994; 36: 362
95. Dart RC, Siefert SA, Carroll L, et al. Human trial of an affinity purified antibody fragment for snake venom poisoning [abstract]. Vet Hum Toxicol 1994; 36: 363
96. Roche Laboratories. Romazicon™ product information. Nutley, NJ: Roche Laboratories, April 1993
97. Lheureux P, Debailleul G, DeWitte O, et al. Zolpidem intoxication mimicking narcotic overdose: response to flumazenil. Hum Exp Toxicol 1990; 9: 105-7
98. Hoffman EJ, Warren EW. Flumazenil: a benzodiazepine antagonist. Clin Pharm 1993; 12: 641-56
99. Brogden RN, Goa KL. Flumazenil: a reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist. Drugs 1991; 42: 1061-89
100. Amrein R, Hetzel W, Hartman D, et al. Clinical pharmacology of flumazenil. Eur J Anaesthesiol 1988; 2 Suppl.: 65-80
101. Höjer J, Baehrendtz S, Magnusson A, et al. A placebo-controlled trial of flumazenil given by continuous infusion in severe benzodiazepine overdosage. Acta Anaesthesiol Scand 1991; 35: 584-90
102. Clark RF, Sage TA, Tungel C, et al. Delayed onsel lorazepam poisoning successfully reversed by flumazenil in a child: case report and review of the literature. Pediatr Emerg Care 1995; 11 (1): 32-4
103. The Flumazenil in Benzodiazepine Intoxication Multicenter Study Group. Treatment of benzodiazepine overdose with flumazenil. Clin Ther 1992; 14: 978-95
104. Haverkos GP, DiSalvo RP, Imhoff TE. Fatal seizures after flumazenil administration in a patient with mixed overdose. Ann Pharmacother 1994; 28: 1347-9
105. Agency for Toxic Substances and Disease Registry (ATSDR), U.S. Department of Health and Human Services, Public Health Service. Case studies in environmental medicine: methanol toxicity. San Rafael, CA: DeLima Associates, July 1992
106. Burkhart KK, Kulig KW. The other alcohols: methanol, ethylene glycol, andisopropanol. Emerg Med Clin North Am 1990; 8: 913-8
107. Brown CG, Trumbull D, Klein-Schwartz W. Ethylene glycol poisoning. Ann Emerg Med 1983; 12: 501-6
108. Berman LB, Schreiner GE, Feys J. The nephrotoxic lesion of ethylene glycol. Ann Intern Med 1957; 46: 611-9
109. Factor SA, Lava NS. Ethylene glycol intoxication: a new stage in the clinical syndrome. NY State J Med 1987; 87: 179-80
110. Kruse JA. Methanol poisoning. Intensive Care Med 1992; 18: 391-7
111. Bolgiano EB, Barish RA. Use of new and established antidotes. Emerg Med Clin North Am 1994; 12: 317-34
112. DaRoza R, Henning RJ, Sunshine I, et al. Acute ethylene glycol poisoning. Crit Care Med 1984; 12 (11): 1003-5
113. McCoy HG, Cipolle RJ, Ehlers SM, et al. Severe methanol poisoning: application of a pharmacokinetic model for ethanol therapy and hemodialysis. Am J Med 1979; 67: 804-7
114. Manoguerra AS, Cipolle RJ, Zaske DE, et al. Serum concentration studies during hemodialysis in a patient with severe methanol intoxication. In: Rumack BH. Temple AR, editors. Management of the Poisoned Patient. Princeton: Science Press, 1977: 103-14
115. Gonda A, Gault H, Churchill D, et al. Hemodialysis for methanol intoxication. Am J Med 1978; 64: 749-58
116. Osterloh JD, Pond SM, Grady S, et al. Serum formate concentrations in methanol intoxication as a criteria tor hemodialysis. Ann Intern Med 1986; 104: 200-3
117. Jacobsen D, Sebastian CS, Barron SK, et al. Effects of 4-methylpyrazole, methanol/ethylene glycol antidote in healthy humans. J Emerg Med 1990; 8: 455-61
118. Jobard E, Harry P, Turcant A, et al. 4-Methylpyrazole and hemodialysis in ethylene glycol poisoning. Clin Toxicol 1996; 34: 373-7
119. Jacobsen D, McMartin K. 4-Methylpyrazole - present status [editorial]. Clin Toxicol 1996; 34: 379-81
120. Yen D, Tsai J, Wang LM, et al. The clinical experience of acute cyanide poisoning. Am J Emerg Med 1995; 13: 524-8
121. Kulling P. Hospital treatment of victims exposed to combustion products. Toxicol Lett 1992; 64-5: 283-9
122. Houeto P, Borron SW, Sandouk P, et al. Pharmacokinetics of hydroxocobalamin in smoke inhalation victims. Clin Toxicol 1996; 34: 397-404
123. 12 in the treatment and prevention of nitroprusside-induced cyanide toxicity. Crit Care Med 1993; 21: 465-7
124. Forsyth JC, Mueller PD, Becker CE, et al. Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers. J Toxicol Clin Toxicol 1993; 31: 277-94
125. Kulig K. Cyanide antidotes and lire toxicology [editorial]. N Engl J Med 1991; 325: 1801-2
126. Baud FJ, Barriot P, Toffis V, et al. Elevated blood cyanide concentrations in victims of smoke inhalation. N Engl J Med 1991; 325: 1761-6
127. Buck ML, Reed MD. Use of nondepolarizing neuromuscular blocking agents in mechanically ventilated patients. Clin Pharm 1991; 10: 32-48
128. Somani SM, Dube SN. Physostigmine - an overview as pretreatment drug for organophosphate intoxication. Int J Clin Pharmacol Ther Toxicol 1989; 27: 367-87
129. Edwards CC. Fight to save FDA and Commissioner Edwards depends on House Commerce Committee commitment to Representative Moss' consumer product bill in conference clash with Magnuson's Senate bill. FDC Reports 1972; 34: 21
130. Buzello W. Postoperative care: antagonism of drugs used in anaesthesia: muscle relaxants. Acta Anaesthesiol Scand 1988; 32 Suppl. 87: 25-7
131. Wachtel RE. Comparison of anticholinesterases and their effects on acetylcholine-activated ion channels. Anesthesiology 1990; 72: 496-503
132. Rumack BH. Anticholinergic poisoning: treatment with physostigmine. Pediatrics 1973; 52: 449-51
133. Feldman MD. The syndrome of anticholinergic intoxication. Am Fam Physician 1986; 34: 113-6
134. Pentel P, Peterson CD. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med 1980; 9: 588-90
135. Smolinske SC. Review of parenteral sulfite reactions. J Toxicol Clin Toxicol 1992; 20: 597-606
136. Ayerst Laboratories Inc. Protopam product information. New York, NY: Ayerst Laboratories Inc., 1991
137. Namba T, Nolte CR, Jackrel J, et al. Poisoning due to organophosphate insecticides. Am J Med 1971; 37: 475-92
138. Wadia RS, Amin RB. Fenthion poisoning [letter]. J Pediatr 1988; 113 (5): 950
139. De Kort WLAM, Kiestra SH, Sangster B. The use of atropine and oximes in organophosphate intoxications: a modified approach. Clin Toxicol 1988; 26: 199-208
140. Kurtz PH. Pralidoxime in the treatment of carbamate intoxication. Am J Emerg Med 1990; 8: 68-70
141. Leikin JB, Paloucek FP. Poisoning & toxicology handbook. Hudson, OH: Lexi-Comp, 1995: 1411-4
142. Taboulet P, Baud FJ, Bismuth C. Clinical features and management of digitalis poisoning - rationale for immunotherapy. J Toxicol Clin Toxicol 1993; 31 (2): 247-60
143. Smith TW, Butler Jr VP, Haber E. Cardiac glycoside-specific antibodies in the treatment of digitalis intoxication. In: Krause R, Haber E, editors. Antibodies in human diagnosis and therapy. New York: Raven Books, 1977: 365-89
144. Hoffman BF, Bigger Jr JT. Digitalis and allied cardiac glycosides. In: Gilman AG, Rall TW, Nies AS, et al., editors. Goodman and Gilman's the pharmacological basis of therapeutics. Elmsford, New York: Pergamon Press, 1990: 815-39
145. Baud FJ, Bismuth C, Pontal PG, et al. Time course of antidigoxin Fab fragments and plasma digitoxin concentrations in an acute digitalis intoxication. J Toxicol Clin Toxicol 1983; 19: 857-60
146. Hickey AR, Wenger TL, Carpenter VP, et al. Digoxin immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol 1991; 17: 590-8
147. Woolf A. Revising the management of digitalis poisoning [editorial]. J Toxicol Clin Toxicol 1993; 31: 275-6
148. Mauskopf JA, Wenger TW. Cost-effectiveness analysis of the use of digoxin immune Fab (Ovine) for treatment of digoxin toxicity. Am J Cardiol 1991; 68: 1709-14
149. Centers for Disease Control/American Thoracic Society. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1993 May 21; 42: 1-8
150. Dutt AK, Stead WW. Tuberculosis. Clin Geriatr Med 1992; 8: 761-75
151. Dhennin C, Vesin L, Feauvcaux J. Burns and the toxic effects of a derivative of hydrazine. Burns Incl Therm Inj 1988; 14: 130-4
152. Boehnert MT, Lewander WJ, Gaudreault P, et al. Advances in clinical toxicology. Pediatr Clin North Am 1985; 32: 193-211
153. Shah BR, Santucci K, Sinert R, et al. Acute isoniazid neurotoxicity in an urban hospital. Pediatrics 1995; 95: 700-4
154. Siefkin AD, Albertson TE, Corbett MG. Isoniazid overdose: pharmacokinetics and effects of oral charcoal in treatment. Hum Toxicol 1987; 6: 497-501
155. Yarbrough BE, Wood JP. Isoniazid overdose treated with high-dose pyridoxine. Ann Emerg Med 1983; 12: 303-5
156. Sievers ML, Merrier RN. Treatment of acute isoniazid toxicity. Am J Hosp Pharm 1975; 32: 202-6
157. Vasile A, Goldberg R, Kornberg B. Pyridoxine toxicity: report of a case. J Am Osteopath Assoc 1984; 83: 790-1
158. Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse. N Engl J Med 1983; 309: 445-8
159. Dalton K, Dalton JY. Characteristics of pyridoxine overdose neuropathy syndrome. Acta Neurol Scand 1987; 76: 8-11
160. Kutt H, Brennan R, Dehejia H, et al. Diphenylhydantoin intoxication. Am Rev Respir Dis 1970; 101: 377-84
161. Glotzer DE, Freedberg KA, Bauchner H. Management of childhood lead poisoning: clinical impact and cost-effectiveness. Med Decis Making 1995; 15: 13-24
162. Mortensen ME, Walson PD. Chelation therapy for childhood lead poisoning. Clin Pediatr 1993; 32: 284-91
163. Glotzer DE. Management of childhood lead poisoning. Pediatr Ann 1994; 23: 606-15
164. Gelman CR, Rumack BH, editors. DRUGDEX Information System. Denver, Colorado: MICROMEDEX, Inc., (edition expired 31 August, 1996)
165. Clarkson TW. Mercury - an element of mystery [editorial]. N Engl J Med 1990; 323: 1137-8
166. Kosnett MJ. Unanswered question in metal chelation. J Toxicol Clin Toxicol 1992; 30: 529-47
167. Levy RS, Fisher M, Alter JN. Penicillamine: review and cutaneous manifestations. J Am Acad Dermatol 1983; 8: 548-88
168. Liebelt EL, Shannon MW. Oral chelators for childhood lead poisoning. Pediatr Ann 1994; 11: 616-9, 623-6
169. Watson WS, Hume R, Moore MR. Oral absorption of lead and iron. Lancet 1980; 2 (8188): 236-7
170. Markowitz ME, Rosen JF, Bijur PE. Effects of iron deficiency on lead excretion in children with moderate lead intoxication. J Pediatr 1990; 116: 360-4
171. Rodriguez LF, Smolik LM, Zhehlik AJ. Benzocaine-induced methemoglobinemia: report of a severe reaction and review of the literature. Ann Pharmacother 1994; 28: 643-9
172. Scott EM. Congenital methemoglobinemia due to DPNH-disphorase deficiency. In: Buetler E, editor. Hereditary disorders of erythrocyte metabolism. New York: Grune and Stratton, 1968: 102
173. Truman TL, Dallessio JJ, Weibley RE. Life-threatening Pyridium Plus intoxication: a case report. Pediatr Emerg Care 1994; 10: 225-8
174. Sills MR, Zinkham WH. Methylene blue-induced heinz body hemolytic anemia. Arch Pediatr Adolesc Med 1994; 148: 306-10
175. Foxworth JW, Roberts JA, Mahmoud SF. Acquired methemoglobinemia: a case report. Mo Med 1987; 84: 187-9
176. Hall AH, Rumack BH. Clinical toxicology of cyanide. Ann Emerg Med 1986; 15: 1067
177. Jones J, McMullen MJ, Dougherty J. Toxic smoke inhalation: cyanide poisoning in fire victims. Am J Emerg Med 1987; 5: 318-21
178. Johnson WS, Hall AH, Rumack BH. Cyanide poisoning successfully treated without 'therapeutic methemoglobin levels'. Am J Emerg Med 1989; 7: 437-40
179. Hall AH, Kulig KW, Rumack BH. Toxic smoke inhalation [editorial]. Am J Emerg Med 1989; 7: 121-2
180. Kirk MA, Gerace R, Kulig KW. Cyanide and methemoglobin kinetics in smoke inhalation victims treated with the cyanide antidote kit. Ann Emerg Med 1993; 22: 1413-8
181. Mann KV, Travers JD. Succimer: an oral lead chelator. Clin Pharm 1991; 10: 914-22
182. McNeil Consumer Products Company. Chemet product information. Fort Washington. PA: McNeil Consumer Products Company, 1994
183. Wegmann K. Chelation therapy to treat lead toxicity in children. Minn Med 1992; 75: 25-7
184. Goldfrank LR. Medical toxicology. JAMA 1992; 268: 375-6
185. Graziano JF, Siris ES, Lolacono N, et al. 2,3 dimercaptosuccinic acid as an antidote for lead intoxication. Clin Pharmacol Ther 1985; 37: 431-8
186. Aposhian HV, Maiorino RM, Gonzalez-Ramirez D, et al. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology 1995; 97: 23-38